Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Shares Acquired by GSA Capital Partners LLP

GSA Capital Partners LLP increased its position in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) by 3,683.6% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 524,676 shares of the biotechnology company’s stock after purchasing an additional 510,809 shares during the period. GSA Capital Partners LLP owned 0.32% of Ironwood Pharmaceuticals worth $771,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in IRWD. Federated Hermes Inc. grew its holdings in shares of Ironwood Pharmaceuticals by 252.3% during the first quarter. Federated Hermes Inc. now owns 1,305,362 shares of the biotechnology company’s stock worth $1,919,000 after buying an additional 934,886 shares during the last quarter. Deutsche Bank AG lifted its position in Ironwood Pharmaceuticals by 47.4% during the 4th quarter. Deutsche Bank AG now owns 1,567,535 shares of the biotechnology company’s stock worth $6,944,000 after acquiring an additional 504,336 shares during the period. Renaissance Technologies LLC grew its stake in shares of Ironwood Pharmaceuticals by 5.5% in the 4th quarter. Renaissance Technologies LLC now owns 9,066,241 shares of the biotechnology company’s stock valued at $40,163,000 after purchasing an additional 469,043 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in shares of Ironwood Pharmaceuticals in the 4th quarter valued at approximately $1,888,000. Finally, Walleye Capital LLC increased its holdings in shares of Ironwood Pharmaceuticals by 107.0% in the fourth quarter. Walleye Capital LLC now owns 580,097 shares of the biotechnology company’s stock valued at $2,570,000 after purchasing an additional 299,798 shares during the period.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the company. Citizens Jmp downgraded Ironwood Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Monday, April 14th. Leerink Partners reduced their target price on shares of Ironwood Pharmaceuticals from $3.00 to $1.00 and set a “market perform” rating for the company in a research note on Monday, April 14th. Wells Fargo & Company reaffirmed an “equal weight” rating and issued a $1.00 target price (down previously from $7.00) on shares of Ironwood Pharmaceuticals in a report on Tuesday, April 15th. Wall Street Zen upgraded shares of Ironwood Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, May 8th. Finally, Jefferies Financial Group restated a “hold” rating and issued a $0.70 price objective (down previously from $8.00) on shares of Ironwood Pharmaceuticals in a research report on Tuesday, April 15th. Seven investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $4.78.

Ironwood Pharmaceuticals Stock Up 1.0%

Shares of IRWD opened at $0.77 on Friday. Ironwood Pharmaceuticals, Inc. has a 52-week low of $0.53 and a 52-week high of $6.57. The company has a 50-day simple moving average of $0.72 and a 200-day simple moving average of $1.28. The company has a market capitalization of $124.83 million, a PE ratio of -3.86 and a beta of 0.33.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last issued its earnings results on Wednesday, May 7th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.09). Ironwood Pharmaceuticals had a negative net margin of 9.89% and a negative return on equity of 1.87%. The company had revenue of $41.14 million during the quarter, compared to analysts’ expectations of $67.02 million. On average, research analysts anticipate that Ironwood Pharmaceuticals, Inc. will post 0.1 EPS for the current year.

Ironwood Pharmaceuticals Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.